Plasma sVCAM-1, antiretroviral therapy and mortality in HIV-1-infected West African adults
| dc.rights.license | open | en_US |
| dc.contributor.author | AFFI, Roseline | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | GABILLARD, Delphine | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | KOUAME, Menan Gerard | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| hal.structure.identifier | Global Health in the Global South [GHiGS] | |
| dc.contributor.author | N'TAKPE, Jean-Baptiste | |
| dc.contributor.author | MOH, Desmorys Raoul | |
| dc.contributor.author | BADJE, Anani Dodzi | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | DANEL, Christine | |
| dc.contributor.author | INWOLEY, Andre | |
| dc.contributor.author | EHOLIE, Serge P | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| hal.structure.identifier | Global Health in the Global South [GHiGS] | |
| dc.contributor.author | ANGLARET, Xavier | |
| dc.contributor.author | WEISS, Laurence | |
| dc.date.accessioned | 2022-03-03T11:18:31Z | |
| dc.date.available | 2022-03-03T11:18:31Z | |
| dc.date.issued | 2022-01-12 | |
| dc.identifier.issn | 1468-1293 (Electronic) 1464-2662 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/128802 | |
| dc.description.abstractEn | OBJECTIVES: We report the association between pre-antiretroviral therapy (pre-ART) soluble vascular cell adhesion molecule-1 (sVCAM-1) levels and long-term mortality in HIV-infected West African adults participating in a trial of early ART in West Africa (Temprano ANRS 12136 trial). METHODS: The ART-naïve HIV-infected adults were randomly assigned to start ART immediately or defer ART until the WHO criteria were met. Participants who completed the trial follow-up were invited to participate in a post-trial phase (PTP). The PTP end-point was all-cause death. We used multivariable Cox proportional models to analyse the association between baseline sVCAM-1 and all-cause death, adjusting for ART strategy, sex, CD4 count, plasma HIV-1 RNA and peripheral blood mononuclear cell HIV-1 DNA levels. RESULTS: In all, 954 adults (77% women, median CD4 count of 387 cells/μL) were randomly assigned to start ART immediately (n = 477) or to defer initiation of ART (n = 477). They were followed for a median of 5.8 years [interquartile range (IQR): 5.2-6.3]. In multivariable analysis, the risk of death was significantly associated with baseline sVCAM-1 [≥1458 vs. < 1458 ng/mL; adjusted hazard ratio = 2.86, 95% confidence interval (CI): 1.60-5.11]. The 6-year probability of death rates were 14.4% (95%CI: 9.1-22.6) and 9.4% (5.4-16.1) in patients with baseline sVCAM-1 ≥ 1458 ng/mL randomized to deferred and immediate ART, respectively, and 3.8% (2.2-6.5) and 3.5% (1.9-6.3) in patients with baseline sVCAM-1 < 1458 ng/mL randomized to deferred and immediate ART. The median difference between pre-ART and 12-month sVCAM-1 levels in patients randomized to immediate ART was -252 (IQR: -587 to -61). CONCLUSIONS: Pre-ART sVCAM-1 levels were significantly associated with mortality, independently of whether ART was started immediately or deferred, but they significantly decreased after 12 months of ART. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Antiretroviral therapy | |
| dc.subject.en | Endothelial dysfunction | |
| dc.subject.en | Mortality | |
| dc.subject.en | Sub-Saharan Africa | |
| dc.title.en | Plasma sVCAM-1, antiretroviral therapy and mortality in HIV-1-infected West African adults | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1111/hiv.13230 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 35023284 | en_US |
| bordeaux.journal | HIV Medicine | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | GHIGS_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | Agence Nationale de Recherches sur le Sida et les Hépatites Virales | en_US |
| hal.identifier | hal-03595705 | |
| hal.version | 1 | |
| hal.date.transferred | 2023-07-05T09:17:32Z | |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=HIV%20Medicine&rft.date=2022-01-12&rft.eissn=1468-1293%20(Electronic)%201464-2662%20(Linking)&rft.issn=1468-1293%20(Electronic)%201464-2662%20(Linking)&rft.au=AFFI,%20Roseline&GABILLARD,%20Delphine&KOUAME,%20Menan%20Gerard&N'TAKPE,%20Jean-Baptiste&MOH,%20Desmorys%20Raoul&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||